Latest Teva data in schizophrenia for long-acting injectable of olanzapine

New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare provider experiences with TEV-‘749, a long-acting injectable formulation of olanzapine that can potentially address the risk of post-injection delirium/sedation syndrome (PDSS), a rare and potentially life-threatening side effect.

These data also highlight broader treatment preferences (eg, treatment initiation, formulation, regimens), underscoring the importance of TEV-‘749 as a potential LAI form of olanzapine, the active ingredient of Zyprexa, developed by Eli Lilly (NYSE: LLY), but which has historically struggled in the long-acting injectable market because of post-injection delirium/sedation syndrome (PDSS) risk associated with the product.

The results from a survey evaluating patient and healthcare provider experiences with TEV-‘749 in the Phase III SOLARIS trial showed that more than 92% of schizophrenia patients were satisfied with its initiation, dosing schedule and dosing options.